{"organizations": [], "uuid": "1d4973c6be148a46e3d52435d29c9c379c8d58b5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-alnylam-receives-european-medicine/brief-alnylam-receives-european-medicines-agency-prime-designation-for-accelerated-assessment-of-lumasiran-idUSFWN1R80DU", "country": "US", "domain_rank": 408, "title": "BRIEF-Alnylam Receives European Medicines Agency Prime Designation For Accelerated Assessment Of Lumasiran", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-26T14:21:00.000+03:00", "replies_count": 0, "uuid": "1d4973c6be148a46e3d52435d29c9c379c8d58b5"}, "author": "", "url": "https://www.reuters.com/article/brief-alnylam-receives-european-medicine/brief-alnylam-receives-european-medicines-agency-prime-designation-for-accelerated-assessment-of-lumasiran-idUSFWN1R80DU", "ord_in_thread": 0, "title": "BRIEF-Alnylam Receives European Medicines Agency Prime Designation For Accelerated Assessment Of Lumasiran", "locations": [], "entities": {"persons": [], "locations": [{"name": "lumasiran", "sentiment": "none"}], "organizations": [{"name": "accelerated assessment of lumasiran", "sentiment": "negative"}, {"name": "brief-alnylam receives european medicines agency", "sentiment": "negative"}, {"name": "alnylam pharmaceuticals inc", "sentiment": "none"}, {"name": "alnylam pharmaceuticals inc", "sentiment": "none"}, {"name": "alnylam", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "accelerated assessment of lumasiran reuters staff", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 22 AM / Updated 12 minutes ago BRIEF-Alnylam Receives European Medicines Agency Prime Designation For Accelerated Assessment Of Lumasiran Reuters Staff 1 Min Read   Alnylam Pharmaceuticals Inc: * ALNYLAM RECEIVES EUROPEAN MEDICINES AGENCY PRIME DESIGNATION FOR ACCELERATED ASSESSMENT OF LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1) * ALNYLAM PHARMACEUTICALS INC - COMPANY INTENDS TO ADVANCE LUMASIRAN TO A PHASE 3 STUDY IN LATE 2018 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-26T14:21:00.000+03:00", "crawled": "2018-03-26T14:43:11.003+03:00", "highlightTitle": ""}